Makoto Ohori
Partner | Chief Investment Officer, Life Science @ UTokyo Innovation Platform
Tokyo, Japan
Makoto Ohori is a Partner and Chief Investment Officer at UTokyo Innovation Platform.Dr. Ohori received his Ph.D. in Pharmaceutical Sciences from the University of Tokyo, where his doctoral research focused on drug discovery and pharmacological evaluation of novel kinase inhibitors for autoimmune diseases. Dr. Ohori has collaborated withvarious institutions, such as Grenoble University Hospital, Kyoto University Hospital, Dokkyo University School of Medicine, Trevigen, Inc etc. He authored more than fifteen peer reviewed articles and invited reviews.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 80%
Last updated:
For AI agents: llms.txt
Industries Makoto Ohori invests in
Stages Makoto Ohori invests in
Countries Makoto Ohori invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (80%)
- Biopharma 3 (60%)
- Medical 2 (40%)
- Life Science 2 (40%)
- Genetics 1 (20%)
Stage
- Series A 1 (20%)
- Series B 1 (20%)
- Series C 1 (20%)
- Venture - Series Unknown 1 (20%)
Country
- Japan 2 (40%)
- United States 2 (40%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
CORE Biomedicine
|
CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology. | $21M / Series A / Jul 28, 2026 | |
Libero Thera
|
LiberoThera provides drug discovery research and development services. It focuses on making drugs with GPCRs for membrane proteins. LiberoThera was founded in 2018 and is located in Tokyo. | $1.3M / Venture - Series Unknown / Aug 01, 2024 | |
AceRNA Technologies
|
AceRNA contributes to regenerative medicine and drug discovery through the discovery of novel miRNA functions. | $6.2M / Series B / May 07, 2024 | |
Vertero
|
Axial Therapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. | $37.3M / Series C / Oct 13, 2021 | |
|
Libero Thera
|
LiberoThera provides drug discovery research and development services. It focuses on making drugs with GPCRs for membrane proteins. LiberoThera was founded in 2018 and is located in Tokyo. | $4.9M / Venture - Series Unknown / May 14, 2021 |
Co-Investors
The University of Tokyo IPC is a company responsible for expanding the innovation ecosystem. Accelerate global innovation from the University of Tokyo through three activities: start-up support, investment business, and corporate innovation support.
UTokyo Innovation Platform Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Makoto Ohori
Partner | Chief Investment Officer, Life Science
|
|||
|
Hiroho Fukuda
Auditor
|
|||
Katsuhiko Oizumi
Founder, President and CEO
|
|||
Kazuhiko Kakehi
Partner,Academic Co-Innovation
|
|||
Kei Furukawa
Manager,Investment and Business Development
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Makoto Ohori invest in?
Makoto Ohori invests primarily in Biotechnology, Biopharma and Medical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Makoto Ohori?
Public channels for Makoto Ohori include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Makoto Ohori last invest?
The most recent investment recorded for Makoto Ohori closed in Jul 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
